2025
Reporting of Fairness Metrics in Clinical Risk Prediction Models Used for Precision Health: Scoping Review
Rountree L, Lin Y, Liu C, Salvatore M, Admon A, Nallamothu B, Singh K, Basu A, Bu F, Mukherjee B. Reporting of Fairness Metrics in Clinical Risk Prediction Models Used for Precision Health: Scoping Review. Online Journal Of Public Health Informatics 2025, 17: e66598. PMID: 39962044, DOI: 10.2196/66598.Peer-Reviewed Original ResearchClinical risk prediction modelsRisk prediction modelFairness metricsSex-stratified modelsEthnicity dataPrecision healthClinical risk predictionSensitive featuresStudy populationCardiovascular diseaseRisk predictionEvaluate potential disparitiesTraining dataPotential disparitiesEmpirical evaluationPrediction modelPrimary preventionInformatics systemsHigh-impact publicationsCOVID-19Metrics usageStudy cohortGoogle ScholarImplementation frameworkCOVID-19 modelThe Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review
Mahabamunuge J, Sekula N, Lepore C, Kudrimoti M, Upadhyay A, Alshowaikh K, Li H, Seifer D, AlAshqar A. The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review. Biomedicines 2025, 13: 709. PMID: 40149685, PMCID: PMC11940587, DOI: 10.3390/biomedicines13030709.Peer-Reviewed Original ResearchPolycystic ovary syndromeType 2 diabetes mellitusCardiometabolic morbidityIncreased cardiovascular riskDevelopment of hypertensionCardiovascular risk factorsNarrative reviewPotential clinical implicationsAndrogen excessEndothelial dysfunctionCardiovascular riskClinical conditionsPredisposed individualsTherapeutic strategiesAdipokine secretionRisk factorsInsulin resistanceCardiometabolic diseasesCardiovascular diseaseClinical implicationsMorbidityMellitusSyndromeMolecular mechanismsDiseaseThe burden of cardiovascular disease in Latin America and the Caribbean, 1990-2019: An analysis of the global burden of disease study
Alhuneafat L, Al Ta'ani O, Arriola-Montenegro J, Al-Ajloun Y, Naser A, Chaponan-Lavalle A, Ordaya-Gonzales K, Pertuz G, Maaita A, Jabri A, Altibi A, Al-Abdouh A, Van't Hof J, Gutierrez Bernal A. The burden of cardiovascular disease in Latin America and the Caribbean, 1990-2019: An analysis of the global burden of disease study. International Journal Of Cardiology 2025, 428: 133143. PMID: 40064205, DOI: 10.1016/j.ijcard.2025.133143.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsGlobal Burden of DiseaseBurden of cardiovascular diseaseCardiovascular diseaseRisk factorsMortality-to-incidence ratioGlobal burdenIschemic heart diseaseAge-standardized disability-adjusted life yearsGlobal Burden of Disease StudyDisability-adjusted life year ratesBurden of Disease StudyAge-standardized prevalenceComparative risk assessment frameworkCardiovascular disease prevalenceCardiovascular disease burdenBurden of diseaseLeading risk factorHeart diseaseTailored interventionsCountry-specific variationsElevated BMIRate of strokeHealthcare infrastructureSocio-economic factorsCardiovascular Event Prevalence in Type 1 Versus Type 2 Diabetes: Veradigm Metabolic Registry Insights
Goldsweig A, Knee A, Tak H, Desai N, Bradley S, Lotfi A, Spertus J, Goldsweig B. Cardiovascular Event Prevalence in Type 1 Versus Type 2 Diabetes: Veradigm Metabolic Registry Insights. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102502. DOI: 10.1016/j.jscai.2024.102502.Peer-Reviewed Original ResearchIncident cardiovascular eventsPrevalence ratiosDiabetes mellitus type 1Risk of incident cardiovascular eventsCardiovascular diseaseCardiovascular eventsPrimary carePercutaneous coronary interventionMyocardial infarctionType 2 diabetesOutpatient facilitiesEvent prevalenceLimb ischemiaCoronary interventionAge categoriesStudy populationDM2 patientsRisk factorsHemoglobin A1cCarePrevalencePeripheral revascularizationInterventionComorbiditiesDM2Underrepresentation and exclusion of patients with cardiovascular disease in intensive care randomized controlled trials
Ali T, Grimshaw A, Thomas A, Solomon M, Ross J, Miller P. Underrepresentation and exclusion of patients with cardiovascular disease in intensive care randomized controlled trials. European Heart Journal Acute Cardiovascular Care 2025, zuaf023. PMID: 39950988, DOI: 10.1093/ehjacc/zuaf023.Peer-Reviewed Original ResearchContemporary cardiac intensive care unitsRandomized controlled trialsIschemic heart diseaseCardiovascular diseaseHeart failureDisciplines of critical care medicineHistory of heart failureProspective randomized controlled trialsHeart diseaseControlled trialsExclusion criteriaMultivariate logistic regression analysisCardiac intensive care unitProportion of patientsExclusion of patientsComorbid cardiovascular diseaseCardiovascular disease historyIntensive care unitLogistic regression analysisApplication of randomized controlled trialsComplex patient populationGeneral internal medicineCardiovascular disease comorbiditiesMulticenter trialIndependent predictorsCorrecting for bias due to mismeasured exposure in mediation analysis with a survival outcome
Cheng C, Spiegelman D, Li F. Correcting for bias due to mismeasured exposure in mediation analysis with a survival outcome. Journal Of The Royal Statistical Society Series C (Applied Statistics) 2025, qlaf010. DOI: 10.1093/jrsssc/qlaf010.Peer-Reviewed Original ResearchExposure-mediator interactionProtective effect of physical activityHealth Professionals Follow-up StudyEffects of physical activityReduced body mass indexExposure measurement errorRisk of cardiovascular diseaseBody mass indexPhysical activityMismeasured exposureMass indexRare outcomesFollow-up studyCardiovascular diseaseMediation analysisCox regressionOutcomesBias formulaSurvival outcomesHealthIntegration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology
Erbay M, Manubolu V, Stein-Merlob A, Ferencik M, Mamas M, Lopez-Mattei J, Baldassarre L, Budoff M, Yang E. Integration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology. Current Cardiology Reports 2025, 27: 51. PMID: 39932640, PMCID: PMC11814013, DOI: 10.1007/s11886-025-02206-x.Peer-Reviewed Original ResearchConceptsRadiation-induced cardiovascular diseaseCoronary artery diseaseCardiovascular diseaseCardiac massComputed tomographyArtery diseaseChest CT scans of patientsCT scans of patientsIncreased risk of CVDInvasive coronary angiographyRisk of cardiovascular diseaseRisk of complicationsScans of patientsCardiovascular computed tomographySeverity of cardiovascular diseaseNon-invasive imaging toolMonitoring of disease progressionManifestations of diseaseAsymptomatic patientsCardiac deteriorationIschemia evaluationCoronary angiographyPericardial diseaseCardiac changesRisk stratificationPower and Sample Size Calculations for Cluster Randomized Hybrid Type 2 Effectiveness‐Implementation Studies
Owen M, Curran G, Smith J, Tedla Y, Cheng C, Spiegelman D. Power and Sample Size Calculations for Cluster Randomized Hybrid Type 2 Effectiveness‐Implementation Studies. Statistics In Medicine 2025, 44: e70015. PMID: 39930740, DOI: 10.1002/sim.70015.Peer-Reviewed Original ResearchConceptsHybrid type 2 effectiveness-implementation studySample size calculationCluster randomized trialCluster randomized designSize calculationImplementation research outcomesReduce cardiovascular diseaseIssue of multiple testingEffective outcomesImplementation outcomesCommunity interventionsControl blood pressureBinary outcomesOutcomes approachLiterature searchMultiple testingCardiovascular diseaseInterventionRandomized trialsStandard statistical methodsBlood pressureOutcomesType 2 studiesLow-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible?
Fuss C. Low-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible? Radiology 2025, 314: e250215. PMID: 39964272, DOI: 10.1148/radiol.250215.Peer-Reviewed Original ResearchDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosisCardiovascular disease, bone fracture, and all-cause mortality risks among postmenopausal women by arthritis and veteran status: A multistate Markov transition analysis
Beydoun H, Beydoun M, Weiss J, Brunner R, Mishra N, Ding M, Wactawski-Wende J, Gradidge P, Liu S, Tsai J. Cardiovascular disease, bone fracture, and all-cause mortality risks among postmenopausal women by arthritis and veteran status: A multistate Markov transition analysis. GeroScience 2025, 1-18. PMID: 39875753, DOI: 10.1007/s11357-025-01527-7.Peer-Reviewed Original ResearchNon-veteransVeteran statusCardiovascular diseaseRelationship of arthritisNon-veteran womenWomen's Health InitiativePostmenopausal womenPrevalence of arthritisAll-cause mortalityBone fracturesAssociated with cardiovascular diseaseAssociated with greater probabilityMultistate Markov modelHealth initiativesAnalyzed longitudinal dataPrevalent arthritisMortality riskMilitary veteransVeteransFracture riskStudy objectiveGreater probabilityCox modelWomenLongitudinal dataAssessing cardiovascular disease risk and social determinants of health: A comparative analysis of five risk estimation instruments using data from the Eastern Caribbean Health Outcomes Research Network
Schwartz J, Howitt C, Raman S, Nair S, Hassan S, Oladele C, Hambleton I, Sarpong D, Adams O, Maharaj R, Nazario C, Nunez M, Nunez-Smith M. Assessing cardiovascular disease risk and social determinants of health: A comparative analysis of five risk estimation instruments using data from the Eastern Caribbean Health Outcomes Research Network. PLOS ONE 2025, 20: e0316577. PMID: 39854547, PMCID: PMC11760610, DOI: 10.1371/journal.pone.0316577.Peer-Reviewed Original ResearchConceptsCardiovascular disease riskSocial determinants of healthDeterminants of healthSocial determinantsRisk estimation toolsCardiovascular diseaseEstimate 10-year CVD riskCVD riskEastern Caribbean Health Outcomes Research NetworkCardiovascular disease risk estimatesHigh riskHigher level of educationHistory of cardiovascular diseaseHigher CVD riskMultivariate logistic regression modelEthnically diverse populationsResource-constrained settingsLogistic regression modelsNon-professional occupationsSDoH variablesLevel of educationSDoHPerceived social statusRisk toolFraminghamBehavioral Medicine Can Tackle Cardiovascular Disease Risk and Burden: A Call for New Priorities
Burg M, Stewart J, Gaffey A, Särnholm J, Vela A, Kovacs R. Behavioral Medicine Can Tackle Cardiovascular Disease Risk and Burden: A Call for New Priorities. Policy Insights From The Behavioral And Brain Sciences 2025 DOI: 10.1177/23727322241306071.Peer-Reviewed Original ResearchCardiovascular disease riskCardiovascular diseaseHealth-related quality of lifeCosts of cardiovascular diseaseBehavioral medicineHealth-related qualityQuality of lifeCardiovascular behavioral medicinePsychosocial healthPsychosocial factorsCV careProfessional groupsDisease riskModify behaviorAnnual costRiskMedicineCareHealthcareHealthTreatment of cardiovascular diseasesTacklesBurdenPreventionTrainingThe Quality of Veterans Healthcare Administration Cardiovascular Care
Le D, Arora B, Kelly F, Waldo S, Raitt M, Heidenreich P, Shah S, Denktas A, Mavromatis K, Council A. The Quality of Veterans Healthcare Administration Cardiovascular Care. JACC Advances 2025, 4: 101533. PMID: 39826437, PMCID: PMC11787423, DOI: 10.1016/j.jacadv.2024.101533.Peer-Reviewed Original ResearchVeterans Healthcare AdministrationCardiovascular careQuality of cardiovascular careQuality of health careNon-VHA providersNon-VHA careNon-VHA facilitiesVeterans receiving careHealth care policyUnique healthcare systemVeteran careHealthcare decisionsCare programCommunity careHealth careCare policyHealthcare administratorsHealthcare systemCareQuality InitiativeVeteransCardiovascular diseaseHealthcare sectorHealthcareProvidersHeart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, Pratley R, Dagogo‐Jack S, Cherney D, Wynant W, Gantz I, Mancuso J, Masiukiewicz U, Cannon C. Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. European Journal Of Heart Failure 2025 PMID: 39792342, DOI: 10.1002/ejhf.3511.Peer-Reviewed Original ResearchEffects of ertugliflozinAdverse eventsAtherosclerotic cardiovascular diseaseHF eventsHeart failureType 2 diabetesStandardized Medical Dictionary for Regulatory ActivitiesDoses of ertugliflozinImpact of ertugliflozinCardiovascular diseaseCox proportional hazards modelsHeart failure outcomesMedical Dictionary for Regulatory ActivitiesProportional hazards modelHHF eventsVERTIS CVPeripheral edemaCardiac failureErtugliflozinAndersen-Gill modelHazards modelFailure outcomesPlaceboCV trialsRecurrent eventsRisk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults.
Mosher C, Osazuwa-Peters O, Nanna M, MacIntyre N, Que L, Palmer S, Jones W, O'Brien E. Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults. Journal Of The American Heart Association 2025, 14: e035010. PMID: 39791395, DOI: 10.1161/jaha.124.035010.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary disease hospitalizationsChronic obstructive pulmonary diseaseAtherosclerotic cardiovascular diseaseSecondary prevention cohortPrevention cohortASCVD hospitalizationRisk of atherosclerotic cardiovascular diseaseHazard ratioHospital outcomesHigh riskRisk factorsCardiovascular disease eventsCardiovascular diseasePrimary prevention cohortIdentified multiple risk factorsRisk of cardiovascular disease eventsMultiple risk factorsPulmonary disease hospitalizationsObstructive pulmonary diseaseOlder AdultsHigh-risk patient cohortASCVD eventsDisease eventsHigh-risk patientsMeta-analysesEffect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2025, 21: 100922. PMID: 39896054, PMCID: PMC11786665, DOI: 10.1016/j.ajpc.2024.100922.Peer-Reviewed Original ResearchVascular risk factorsGLP-1 RAsRisk factorsType 2 diabetesAtherosclerotic cardiovascular diseaseUS electronic health records databaseElectronic health record databaseOW GLP-1 RAsRisk factor valuesHealth record databaseCardiovascular diseaseReal-world practiceBody mass indexOnce-weeklyEffects of glucagon-like peptide-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsGLP-1Systolic blood pressureLow-density lipoprotein cholesterolPeptide-1 receptor agonistsEffects of once-weeklyMass indexRecord databaseSignificant mean reductionAssociated with significant reductionsA genetic exploration of the relationship between posttraumatic stress disorder and cardiovascular diseases
Lukas E, Veeneman R, Smit D, Ahluwalia T, Vermeulen J, Pathak G, Polimanti R, Verweij K, Treur J. A genetic exploration of the relationship between posttraumatic stress disorder and cardiovascular diseases. Translational Psychiatry 2025, 15: 1. PMID: 39755697, PMCID: PMC11700205, DOI: 10.1038/s41398-024-03197-z.Peer-Reviewed Original ResearchPosttraumatic stress disorderMendelian randomizationCardiovascular diseaseCausal pathwaysData of genome-wide association studiesGenetic liabilityMultivariable Mendelian randomizationWaist-to-hip ratioPotential mediatorsWaist-to-hipRisk of cardiovascular diseaseGenome-wide association studiesPotential causal pathwaysPrevent cardiovascular diseaseStress disorderIncreased risk of cardiovascular diseaseGenomic structural equationSignificant genetic correlationsPsychosocial factorsEffects of posttraumatic stress disorderAssociation studiesIncreased riskPosttraumatic stress disorder patientsCausal effectsTraumatic eventsChapter 14 Impact of androgens on cardiovascular risk in women with polycystic ovary syndrome and transgender men
Stachenfeld N, Alexander L, Bender J, Weinzimer S, Pal L, Reckelhoff J. Chapter 14 Impact of androgens on cardiovascular risk in women with polycystic ovary syndrome and transgender men. 2025, 279-293. DOI: 10.1016/b978-0-443-22266-5.00014-8.Peer-Reviewed Original ResearchGender-affirming hormone therapyAE-PCOSTransgender menPolycystic ovary syndromeFemale endocrinopathyHigher androgenLong-term consequencesMild hypertensionEndothelial dysfunctionAssociated with endothelial dysfunctionIncreased risk of endothelial dysfunctionRisk of endothelial dysfunctionMenImpact of androgensHyperandrogenemiaHormone therapyHigher androgen levelsInfertilityAndrogen levelsCardiovascular riskVascular systemIncreased riskMetabolic dysfunctionVascular functionCardiovascular disease
2024
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen A, Hajduk A, Grimshaw A, Fried T, Jastreboff A, Lipska K. Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity 2024 PMID: 39725567, DOI: 10.1002/oby.24160.Peer-Reviewed Original ResearchOlder adultsAntiobesity medicationsStudy of older adultsOlder adults ageAdult ageCardiovascular diseaseRisk of biasAdverse events associated with useWeight reductionStatistically significant weight reductionFood and Drug AdministrationClinical careSystematic reviewInclusion criteriaLimited evidenceBaseline weightPlacebo groupObservational studySeven medicationsAdverse eventsAdultsDrug AdministrationEvaluation studiesMedicationSignificant weight reduction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply